Progress of mesenchymal stem cell-derived exosomes for management of preeclampsia
10.3760/cma.j.cn113903-20210812-00700
- VernacularTitle:间充质干细胞来源的外泌体在子痫前期中的实验研究进展
- Author:
Haoran SHI
1
;
Yin ZHAO
Author Information
1. 华中科技大学同济医学院附属协和医院妇产科，武汉 430022
- Keywords:
Pre-eclampsia;
Mesenchymal stem cells;
Exosomes;
Feasibility studies
- From:
Chinese Journal of Perinatal Medicine
2022;25(2):154-157
- CountryChina
- Language:Chinese
-
Abstract:
Pre-eclampsia is a common complication of pregnancy that can result in serious consequences for mother and child health, but there are currently no established therapeutic options. Mesenchymal stem cell-derived exosomes (MSC-exos) are nanoparticles carrying bioactive substances such as proteins, lipids, and nucleic acids, and serve as a medium of intercellular communication. MSC-exos are involved in many important physiological processes, including immunological regulation, cell proliferation and migration, and angiogenesis, thereby play an important role in tissue repair and potentially clinical treatment strategies. In recent years, the treatment strategies of MSC-exos have become an emerging hot topic in the management of ischemic diseases, immune dysfunction, inflammatory diseases, and other fields. We review the advantages and challenges of MSC-exos as a new acellular therapy strategy as well as the feasibility of MSC-exos in managing preeclampsia, from its biological role in the important pathogenesis of preeclampsia, such as trophoblastic and endothelial cell dysfunction, immune imbalance at the maternal-fetal interface, and oxidative stress, and summarize the progress of animal experimental research in this field.
